Want to see STLN full AI Analyst Report?
Starling Oncology Institute (STLN) Ratios
213 Followers
Starling Oncology Institute Ratios
STLN's free cash flow for Q2 2026 was $11.03M. For the 2026 fiscal year, STLN's free cash flow was decreased by $-908.00K and operating cash flow was $11.94M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.59 | 2.15 | 4.12 | 4.39 | 5.17 |
| Quick Ratio | 1.35 | 1.96 | 3.73 | 4.08 | 4.95 |
| Cash Ratio | 0.47 | 0.95 | 0.96 | 0.47 | 3.84 |
| Solvency Ratio | -0.30 | -0.35 | -0.51 | 0.03 | -0.08 |
| Operating Cash Flow Ratio | -0.35 | -0.51 | -1.04 | -2.08 | -1.10 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | -178.58 |
| Net Current Asset Value | $ -67.63M | $ -56.71M | $ -8.72M | $ -8.07M | $ 54.78M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.63 | 0.71 | 0.57 | 0.41 | 0.00 |
| Debt-to-Equity Ratio | -6.60 | 34.31 | 2.10 | 0.88 | 0.00 |
| Debt-to-Capital Ratio | 1.18 | 0.97 | 0.68 | 0.47 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 1.25 | 0.96 | 0.60 | 0.40 | 0.00 |
| Financial Leverage Ratio | -10.47 | 48.12 | 3.67 | 2.12 | 1.95 |
| Debt Service Coverage Ratio | -3.76 | -6.79 | -8.00 | -16.50 | -82.25 |
| Interest Coverage Ratio | -3.20 | -8.02 | -11.36 | -20.08 | -143.31 |
| Debt to Market Cap | 0.14 | 4.02 | 0.58 | 0.67 | 0.00 |
| Interest Debt Per Share | 1.24 | 1.74 | 1.71 | 1.54 | 0.01 |
| Net Debt to EBITDA | -1.65 | -1.44 | -1.59 | -1.39 | 2.71 |
| Profitability Margins | |||||
| Gross Profit Margin | 15.20% | 13.73% | 18.37% | 20.63% | 20.12% |
| EBIT Margin | -9.84% | -14.53% | -18.55% | -28.52% | -22.36% |
| EBITDA Margin | -8.46% | -12.93% | -16.74% | -26.77% | -20.71% |
| Operating Profit Margin | -7.18% | -15.28% | -23.75% | -32.46% | -22.59% |
| Pretax Profit Margin | -12.08% | -16.44% | -25.63% | -0.04% | -5.71% |
| Net Profit Margin | -12.06% | -16.44% | -25.62% | 0.06% | -5.38% |
| Continuous Operations Profit Margin | -12.06% | -16.44% | -25.62% | 0.06% | -5.38% |
| Net Income Per EBT | 99.78% | 100.00% | 99.96% | -167.03% | 94.21% |
| EBT Per EBIT | 168.33% | 107.56% | 107.90% | 0.11% | 25.29% |
| Return on Assets (ROA) | -36.81% | -37.44% | -39.70% | 0.06% | -5.37% |
| Return on Equity (ROE) | 385.53% | -1801.70% | -145.67% | 0.12% | -10.49% |
| Return on Capital Employed (ROCE) | -38.51% | -49.89% | -44.15% | -35.33% | -26.41% |
| Return on Invested Capital (ROIC) | -35.70% | -47.23% | -42.58% | 57.65% | -24.86% |
| Return on Tangible Assets | -41.39% | -42.91% | -45.12% | 0.07% | -6.89% |
| Earnings Yield | -11.31% | -278.86% | -55.21% | 0.13% | -1.69% |
| Efficiency Ratios | |||||
| Receivables Turnover | 8.47 | 8.08 | 7.56 | 6.24 | 9.56 |
| Payables Turnover | 9.88 | 13.95 | 18.34 | 21.38 | 10.42 |
| Inventory Turnover | 25.26 | 33.81 | 19.35 | 21.64 | 25.19 |
| Fixed Asset Turnover | 15.21 | 10.44 | 8.10 | 7.64 | 48.43 |
| Asset Turnover | 3.05 | 2.28 | 1.55 | 0.96 | 1.00 |
| Working Capital Turnover Ratio | 0.00 | 4.66 | 3.10 | 2.24 | 3.24 |
| Cash Conversion Cycle | 20.56 | 29.80 | 47.27 | 58.25 | 17.67 |
| Days of Sales Outstanding | 43.07 | 45.17 | 48.31 | 58.45 | 38.20 |
| Days of Inventory Outstanding | 14.45 | 10.80 | 18.86 | 16.87 | 14.49 |
| Days of Payables Outstanding | 36.96 | 26.16 | 19.90 | 17.07 | 35.02 |
| Operating Cycle | 57.52 | 55.96 | 67.17 | 75.32 | 52.69 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.27 | -0.35 | -0.49 | -0.85 | -0.49 |
| Free Cash Flow Per Share | -0.30 | -0.40 | -0.55 | -0.92 | -0.54 |
| Dividend Paid and CapEx Coverage Ratio | -7.68 | -7.00 | -7.95 | -11.17 | -10.73 |
| Capital Expenditure Coverage Ratio | -7.68 | -7.00 | -7.95 | -11.17 | -10.73 |
| Operating Cash Flow Coverage Ratio | -0.24 | -0.22 | -0.30 | -0.57 | -178.58 |
| Operating Cash Flow to Sales Ratio | -0.05 | -0.07 | -0.11 | -0.24 | -0.16 |
| Free Cash Flow Yield | -5.19% | -130.78% | -27.17% | -56.02% | -5.53% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -10.74 | -0.44 | -1.81 | 790.19 | -59.10 |
| Price-to-Sales (P/S) Ratio | 1.07 | 0.06 | 0.46 | 0.48 | 3.18 |
| Price-to-Book (P/B) Ratio | -34.09 | 6.46 | 2.64 | 0.98 | 6.20 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -19.28 | -0.76 | -3.68 | -1.79 | -18.07 |
| Price-to-Operating Cash Flow Ratio | -21.79 | -0.87 | -4.14 | -1.94 | -19.76 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.02 | 0.00 | -7.86 | 1.77 |
| Enterprise Value Multiple | -14.25 | -1.90 | -4.36 | -3.17 | -12.65 |
| Enterprise Value | 605.98M | 96.67M | 236.63M | 214.28M | 531.63M |
| EV to EBITDA | -14.25 | -1.90 | -4.36 | -3.17 | -12.65 |
| EV to Sales | 1.21 | 0.25 | 0.73 | 0.85 | 2.62 |
| EV to Free Cash Flow | -21.81 | -3.19 | -5.79 | -3.18 | -14.88 |
| EV to Operating Cash Flow | -24.65 | -3.64 | -6.52 | -3.47 | -16.27 |
| Tangible Book Value Per Share | -0.37 | -0.25 | 0.43 | 1.15 | 0.90 |
| Shareholders’ Equity Per Share | -0.17 | 0.05 | 0.77 | 1.69 | 1.57 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 2.67 | 0.06 |
| Revenue Per Share | 5.44 | 5.24 | 4.40 | 3.47 | 3.07 |
| Net Income Per Share | -0.66 | -0.86 | -1.13 | 0.00 | -0.16 |
| Tax Burden | 1.00 | 1.00 | 1.00 | -1.67 | 0.94 |
| Interest Burden | 1.23 | 1.13 | 1.38 | 0.00 | 0.26 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.01 | 0.03 | 0.05 | 0.11 | 0.12 |
| Income Quality | 0.41 | 0.50 | 0.44 | -406.29 | 2.99 |
Currency in USD
